Companies · Pharmaceuticals

Har-Kcy, Llc

LOS ANGELES · Pharmaceuticals

Diligence memoA one-page analyst read on Har-Kcy, Llc — recommendation, valuation, rhythm, risks.→
$3.0M
Total raised · real
1
Rounds
—
Latest step-up
Top 67%
Sector rank · raised
Seed
Latest stage · inferred · Thu Nov 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Har-Kcy, Llc looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.90× the median modeled value of Seed Pharmaceuticals companies in 2016–2018 (71 peers) — value vs value, same stage and era.
  • Issuer reports no revenue, yet is modeled well above niche peers.
Dormant
  • Last raise 9.6 yr ago; this sector typically re-raises about every 13 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Har-Kcy, Llc behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
9.9 yr record
Peak capital year was 2016 with $3.0M across 1 filings.
Market position
ahead of 34% of Pharmaceuticals peers
Capital scale is ahead of 34% of Pharmaceuticals peers; modeled value is above 57% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2016: $3.0M across 1 filings.
  • Largest single filing was $3.0M on 2016-11-17.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Har-Kcy, Llc is one of 1613 Pharmaceuticals companies tracked from LOS ANGELES. By capital raised it ranks in the long tail (ahead of 34% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
No revenue
Issuer revenue
Rule 505
Reg D exemption
5
Investors (latest)
2016
Year incorporated
2016-11-17
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2016-11-17 Raised $3.0M (real) Modeled valuation $114M (est)$3.0M$114MSeed2016

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$3.0M · 2016

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$114.3M
Base estimate est.
$2.3M
Conservative case
$896.9M
Upside case
$15.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seed — a $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
34%
Survival probability
15% low · 52% high
1.68×/yr
Annual markup
2.20×/yr upside case
6.0 yr
Elapsed time used
9.6 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
—
Avg between rounds
—
Capital velocity
9.9 yr
On record since
2016
First round
1
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages)▼ 0.4× of median
This company$3.0M
Sector median$8.1M
Latest round — vs other Seed rounds in sector (real $, this stage)▲ 1.8× above median
This company$3.0M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages)▲ 1.5× above median
This company$114.3M
Sector median$76.1M

Raised more than 34% of sector peers (real $). Modeled value above 57% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #12 of 71.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0MCapital raised (log)Chase Therapeutics Corp · Seed Raised $5.3M · modeled $152.2M (est)Acura Pharmaceuticals, Inc · Seed Raised $4.0M · modeled $152.2M (est)Paragon Biosciences Skyline Capital, LLC · Seed Raised $4.0M · modeled $150.9M (est)Phoenix PharmaLabs Inc · Seed Raised $3.5M · modeled $133.1M (est)Saghmos Therapeutics, Inc. · Seed Raised $3.5M · modeled $133.1M (est)Immucell Corp /De/ · Seed Raised $3.5M · modeled $131.8M (est)Madrigal Pharmaceuticals, Inc. · Seed Raised $3.4M · modeled $128.4M (est)Hydropothecary Corp · Seed Raised $3.3M · modeled $124.6M (est)SapVax, LLC · Seed Raised $3.3M · modeled $123.6M (est)VersaPeutics, Inc. · Seed Raised $3.8M · modeled $121.7M (est)Westwood Life Sciences, Llc · Seed Raised $3.1M · modeled $116.3M (est)Har-Kcy, Llc (this company) Raised $3.0M · modeled $114.3M (est)Har-Kcy, Llc
CompanyStageRaised · realValue · estvs peer med.
Chase Therapeutics CorpSeed$5.3M$152.2M2.52×
Acura Pharmaceuticals, IncSeed$4.0M$152.2M2.52×
Paragon Biosciences Skyline Capital, LLCSeed$4.0M$150.9M2.50×
Phoenix PharmaLabs IncSeed$3.5M$133.1M2.21×
Saghmos Therapeutics, Inc.Seed$3.5M$133.1M2.21×
Immucell Corp /De/Seed$3.5M$131.8M2.19×
Madrigal Pharmaceuticals, Inc.Seed$3.4M$128.4M2.13×
Hydropothecary CorpSeed$3.3M$124.6M2.07×
SapVax, LLCSeed$3.3M$123.6M2.05×
VersaPeutics, Inc.Seed$3.8M$121.7M2.02×
Westwood Life Sciences, LlcSeed$3.1M$116.3M1.93×
Har-Kcy, Llc this companySeed$3.0M$114.3M1.90×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$3.0M2016-11-17$15.0M$114.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$3.0M2016-11-17
    • First recorded raise — entered as Seed.
    • 5 investors on this round.
Intelligence
—
Modeled next raise
$4.8M
Modeled next size est.range $3.1M–$7.7M
—
Last step-up
—
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Harvey A Bookstein—1 other2016-11
Registry & provenance

Har-Kcy, Llc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1690804
SEC CIK
2016
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Censa Pharmaceuticals Inc.PharmaceuticalsSeed$3.0M$57.1Msame sector · same stage
Cairn Therapeutics, Inc.PharmaceuticalsSeed$3.0M$62.6Msame sector · same stage
Apertor Pharmaceuticals, Inc.PharmaceuticalsSeed$3.0M$95.3Msame sector · same stage
Balto Therapeutics, LLCPharmaceuticalsSeed$3.0M$114.1Msame sector · same stage
Ethicann Pharmaceuticals Inc.PharmaceuticalsSeed$3.0M$49.6Msame sector · same stage
Lysoclear, Inc.PharmaceuticalsSeed$3.0M$114.1Msame sector · same stage
Millennial Benefit Management CorpPharmaceuticalsSeed$3.0M$114.1Msame sector · same stage
Oceana Therapeutics, Inc.PharmaceuticalsSeed$3.0M$114.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
IRR, Inc.PharmaceuticalsPre-Seed$7.1M80%
Havix Group, IncPharmaceuticalsSeed$22.8M80%
Havah Therapeutics, Inc.PharmaceuticalsPre-Seed$2.5M79%
Hapten Sciences, Inc.PharmaceuticalsSeed$64.2M79%
Sator Holdings LLCPharmaceuticalsPre-Seed$11.8M79%
KSQ Therapeutics, Inc.PharmaceuticalsSeries C$2.8B78%
Kp Biosciences, Inc.PharmaceuticalsPre-Seed$13.2M78%
Kortuc Usa Inc.PharmaceuticalsSeries D+$1.7B77%
Frequently asked
How much funding has Har-Kcy, Llc raised?
Har-Kcy, Llc has raised approximately $3.0M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Har-Kcy, Llc's estimated valuation?
Provath's modeled valuation for Har-Kcy, Llc is approximately $114.3M (modeled range $2.3M–$896.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Har-Kcy, Llc at?
Har-Kcy, Llc's latest modeled financing stage is Seed. Its most recent recorded round closed around Thu Nov 17.
What does Har-Kcy, Llc do and where is it based?
Har-Kcy, Llc operates in the Pharmaceuticals sector, based in LOS ANGELES.
Explore related

See where Har-Kcy, Llc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Har-Kcy, Llc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.